Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Authors
Bowyer, SPrithviraj, P
Lorigan, Paul C
Larkin, J
McArthur, G
Atkinson, V
Millward, M
Khou, M
Diem, S
Ramanujam, S
Kong, B
Liniker, E
Guminski, A
Parente, P
Andrews, M C
Parakh, S
Cebon, J
Long, G
Carlino, M
Klein, O
Affiliation
Rockingham General Hospital, Cooloongup, Western Australia, AustraliaIssue Date
2016-05-10
Metadata
Show full item recordAbstract
Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy.Citation
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. 2016, 114 (10):1084-9 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2016.107PubMed ID
27124339Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2016.107